XERS
$5.61
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Recent News
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles
Xeris Biopharma Holdings (NasdaqGS:XERS) has reported financial self-sustainability and its first full year of net income. Recent results are supported by strong revenue contribution from its core product portfolio. The company is pursuing multiple patent infringement lawsuits to protect Recorlev from generic challengers. At a share price of $6.02, Xeris Biopharma sits after a 63.1% return over the past year and a 3-year gain of 315.2%. The stock has seen a 7-day return of an 8.5% decline,...
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Xeris Biopharma Holdings Inc (XERS) reports robust financial performance with significant revenue growth and strategic plans for 2026, despite ongoing legal challenges.
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary
Moby summary of Xeris Biopharma Holdings, Inc.'s Q4 2025 earnings call
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
Now as we enter 2026, we do so with clear momentum positioned to drive rapid revenue growth, execute on our advanced pipeline and thoughtfully prepare for even greater opportunities ahead. The performance you delivered in 2025 and the strength of our outlook for 2026 is a direct result of your extraordinary commitment, focus and disciplined execution across every part of our enterprise. Fourth quarter total revenue grew 43% year-over-year to nearly $86 million.
Xeris Biopharma Q4 Earnings Call Highlights
Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a “defining milestone” for the company: financial self-sustainability. On its fourth quarter earnings call, executives also outlined a 2026 outlook calli